Quinsair

June 14, 2016June 14, 2016

New Data on Phase 3 Trial of Quinsair for Cystic Fibrosis Presented by Raptor at European CF Conference

Cystic Fibrosis, News

At the 39th European Cystic Fibrosis Conference, recently held in Basel, Switzerland, Raptor Pharmaceutical presented new data on its Phase 3 MPEX-209 clinical trial comparing Quinsair to inhaled tobramycin solution in patients ... Read more

April 12, 2016April 19, 2016

Quinsair Inhaled Therapy for Cystic Fibrosis Is Launched in Europe, Raptor Announces

Cystic Fibrosis, News

Raptor Pharmaceutical Corp. announced its first commercial sale of Quinsair, a levofloxacin inhalation solution, in Germany and Denmark. The European Union (EU) and Canada have already approved Quinsair for the management of ... Read more

October 6, 2015November 5, 2015

Raptor Pharmaceutical Acquires Rights To Long-Term Treatment Quinsair For Lung Infections Common in CF Patients

Cystic Fibrosis, News

Raptor Pharmaceutical Corp., a global biopharmaceutical company focused on the development and commercialization of transformative therapeutics for rare, debilitating and often fatal diseases, recently announced that it has acquired the ... Read more

August 21, 2015November 6, 2015

Raptor Pharmaceutical Expands Its Rare Disease Portfolio For CF, Bronchiectasis By Acquiring Quinsair

Bronchiectasis, News

Raptor Pharmaceutical Corp. recently announced it has signed an agreement with Tripex Pharmaceuticals in order to acquire Quinsair, which is the first inhaled fluoroquinolone that received approval to manage chronic pulmonary infections caused Pseudomonas ... Read more

December 29, 2014November 5, 2015

Quinsair Treatment For Pseudomonas Aeruginosa in Adult CF Patients Picks Up Positive CHMP Opinion

Cystic Fibrosis, News

The Committee for Medicinal Products for Human Use (CHMP) recently announced a positive comment for the pharmaceutical compound Quinsair, a nebuliser solution administered in a 240 mg dose, based on ... Read more